- Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan
-
Huang CF, Dai CY, Lin YH, Wang CW, Jang TY, Liang PC, Lin TC, Tsai PC, Wei YJ, Yeh ML, Hsieh MY, Huang CK, Huang JF, Chuang WL, Yu ML
- KMID: 2560091
- Clin Mol Hepatol.
- 2024 Oct;30(4):883-894.
- doi: 10.3350/cmh.2024.0414
Background/Aims: Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
-
Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML
- KMID: 2511467
- Clin Mol Hepatol.
- 2021 Jan;27(1):186-196.
- doi: 10.3350/cmh.2020.0180
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug... -
- CITED
-
- Close
- SHARE
-
- Close
